Related references
Note: Only part of the references are listed.Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
Edmund A. Rossi et al.
BLOOD (2009)
Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy
Robert T. O'Donnell et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts
Robert T. O'Donnell et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma
Arturo Molina
ANNUAL REVIEW OF MEDICINE (2008)
Durable Complete Responses From Therapy With Combined Epratuzumab and Rituximab Final Results From an International Multicenter, Phase 2 Study in Recurrent, Indolent, Non-Hodgkin Lymphoma
John P. Leonard et al.
CANCER (2008)
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action
Zhengxing Qu et al.
BLOOD (2008)
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies
J. P. Leonard et al.
ONCOGENE (2007)
Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma
Bridgette Collins-Burow et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo
Karen M. Haas et al.
JOURNAL OF IMMUNOLOGY (2006)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
Sandra J. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms
JC Poe et al.
NATURE IMMUNOLOGY (2004)
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
R Repp et al.
BRITISH JOURNAL OF CANCER (2003)
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
JM Tuscano et al.
BLOOD (2003)
Share Paper
